This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

52/100

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Biomarkers

Topic: Plasma and spinal-fluid biomarkers

Elevated CSF p-Tau181 and NfL levels were associated with greater decline in memory and executive function. Among plasma biomarkers, p-Tau217 and GFAP showed the strongest associations with widespread cognitive decline, particularly in language, visuospatial, and executive domains. These associations were independent of age at onset, clinical phenotype, and APOE ε4 status. DISCUSSION/ Our findings highlight the potential prognostic value of fluid biomarkers in AD, especially CSF p-Tau181 and NfL, and plasma p-Tau217 and GFAP. These results suggest promise for improving disease monitoring, although prognostic utility at the individual level remains uncertain.

Key findings

Elevated CSF p-Tau181 and NfL levels were associated with greater decline in memory and executive function.
Among plasma biomarkers, p-Tau217 and GFAP showed the strongest associations with widespread cognitive decline, particularly in language, visuospatial, and executive domains.
These associations were independent of age at onset, clinical phenotype, and APOE ε4 status.
DISCUSSION/ Our findings highlight the potential prognostic value of fluid biomarkers in AD, especially CSF p-Tau181 and NfL, and plasma p-Tau217 and GFAP.
These results suggest promise for improving disease monitoring, although prognostic utility at the individual level remains uncertain.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants136
Evidence strengthLow

How this study scored 52/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 29 of the 56 points we could judge it on, which is 52 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of neurology)
Journal's citation record	— / 4	No journal record from OpenAlex — left out of this score
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	136 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	— / 7	No citation count (not found in OpenAlex) — left out of this score
Citations per year	— / 5	No citation count or no year — left out of this score
Impact for its field and year	— / 6	No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here	— / 6	Not yet checked against this library's citation graph — left out of this score
Still being cited	— / 4	No yearly citation counts — left out of this score
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multi-centre collaboration	— / 3	Institutions not listed — left out of this score
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41402627)
Free to read	— / 2	Access not recorded — left out of this score
Points	29 / 56	Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 29 of the 56 points we could judge it on is 52 out of 100.
Total	52 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Guillén, N., Esteller, D., Sarto, J., Perales, I., Ríos-Guillermo, J., Massons, M., et al. (2025). Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease. Journal of neurology. https://doi.org/10.1007/s00415-025-13556-5

Vancouver

Guillén N, Esteller D, Sarto J, Perales I, Ríos-Guillermo J, Massons M, et al. Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease. Journal of neurology. 2025. doi:10.1007/s00415-025-13556-5. PMID: 41402627.

BibTeX

@article{guillen2025-41402627,
  author  = {Guillén, Núria and Esteller, Diana and Sarto, Jordi and Perales, Iria and Ríos-Guillermo, Jose and Massons, Miquel and Martín-Sobrino, Isabel and Augé, Josep Maria and others},
  title   = {{Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease}},
  journal = {Journal of neurology},
  year    = {2025},
  doi     = {10.1007/s00415-025-13556-5},
  pmid    = {41402627},
  url     = {https://doi.org/10.1007/s00415-025-13556-5}
}

Related studies in Biomarkers

Also tagged “blood-based”

698 studies in the library carry the topic tag “blood-based”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 698 tagged studies.

Similar studies

More on Biomarkers

See all studies in Biomarkers →